Takeda Pharmaceutical (TAK) Free Cash Flow Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 39.19% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 31.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.64% |
| Dec 31, 2025 | -2.56% |
| Sep 30, 2025 | 16.14% |
| Jun 30, 2025 | 23.04% |
| Mar 31, 2025 | -37.58% |
| Dec 31, 2024 | -5.05% |
| Sep 30, 2024 | -2.60% |
| Jun 30, 2024 | -6.62% |
| Mar 31, 2024 | -27.90% |
| Dec 31, 2023 | -17.37% |
| Sep 30, 2023 | -13.98% |
| Jun 30, 2023 | -13.71% |
| Mar 31, 2023 | 36.76% |
| Sep 30, 2022 | -27.46% |
| Jun 30, 2022 | -10.65% |
| Mar 31, 2022 | 186.36% |
| Dec 31, 2021 | 51.81% |
| Sep 30, 2021 | 41.10% |
| Jun 30, 2021 | 48.29% |
| Mar 31, 2021 | 76.41% |